1stOncology™: Cancer Intelligence Service – Page 5893 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

On September 6, 2022 Milestone Pharmaceuticals Inc. ( Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, reported that Joseph Oliveto, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 12:00 p.m. ET in New York, NY (Press release, Milestone Pharmaceuticals, SEP 6, 2022, https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301617233.html [SID1234619109]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed in the News & Events section of Milestone’s website at www.milestonepharma.com. An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

On September 6, 2022 DURECT Corporation ( Nasdaq: DRRX) reported that Dr. James E. Brown, President and CEO will be presenting virtually at the H.C. Wainwright 24th annual Global Investment Conference (Press release, DURECT, SEP 6, 2022, https://www.prnewswire.com/news-releases/durect-corporation-to-present-at-the-hc-wainwright-global-investment-conference-301617467.html [SID1234619107]).

The webcast link of the presentation will also be available by accessing DURECT’s homepage at www.durect.com and clicking on "Event Calendar" under the "Investors" section.

Management will also be available for virtual 1×1 meetings from September 12-14, 2022 during the conference. If attendees would like to request a meeting, please contact H.C. Wainwright directly.

Insmed To Present at Two September Conferences

On September 6, 2022 Insmed Incorporated ( Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that management will present at the following investor events (Press release, Insmed, SEP 6, 2022, View Source [SID1234619106]):

The Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY on September 12, 2022 at 9:55 a.m. ET in a fireside chat
The H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on September 13, 2022 at 5:00 p.m. ET in a fireside chat
Each fireside chat will be webcast and can be accessed by visiting the investor relations section of the Company’s website at www.insmed.com. Each webcast will be archived for a period of 30 days following the respective presentation dates.

I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

On September 6, 2022 I-Mab (the "Company") ( Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, reported that the results from its Phase 2 clinical study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be featured in a proffered paper presentation at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022, on Saturday, September 10 at 2:45 p.m. CET (Press release, I-Mab Biopharma, SEP 6, 2022, View Source [SID1234619105]). The Company will host a conference call with investors to provide an in-depth data analysis on Monday, September 12.

About CD47 and Lemzoparlimab

CD47 is a cell surface protein over-expressed in a wide variety of cancers and can act to protect tumors by delivering a "don’t eat me" signal to otherwise tumor-engulfing macrophages. CD47 antibody blocks this signal and enables macrophages to attack tumor cells. However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. Scientists at I-Mab discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.

Multiple clinical studies of lemzoparlimab are ongoing to explore indications in treating patients with myelodysplastic syndrome (MDS), acute myelocytic leukemia (AML), non-Hodgkin’s lymphoma (NHL), and advanced solid tumors in combination with chemotherapy and immune checkpoint inhibitors.

Aethlon Medical to Present at Two Investor Conferences in September

On September 6, 2022 Aethlon Medical, Inc. ( Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, reported that it will be presenting at two investor conferences in September (Press release, Aethlon Medical, SEP 6, 2022, View Source [SID1234619104]). These include the H.C. Wainwright 24th Annual Global Investment Conference, being held virtually and in New York from Sept. 12-14, 2022, and the Life Sciences Investor Forum, being held virtually on Sept. 15, 2022. At both conferences, Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Officer, and James Frakes, Chief Financial Officer, will present an overview of Aethlon Medical.

At the H.C. Wainwright conference, Aethlon’s pre-recorded presentation will be available on-demand beginning Monday, Sept. 12 at 7:00 a.m. EDT at the link below and will be archived for 90 days. In addition to the overview presentation, Aethlon leadership will be hosting virtual one-on-one meetings at the conference on Wednesday, Sept. 14. At the Life Sciences Investor Forum, Aethlon’s presentation will be broadcast at 2 p.m. EDT on Thursday, Sept. 15 and will be followed by a live question and answer session. The Aethlon leadership team will also be hosting virtual one-on-one meetings at this conference. Both conference presentations will be available on the Aethlon website.

Details regarding the two conference presentations can be seen below.

Event: H.C. Wainwright 24th Annual Global Investment Conference
Date: Monday, Sept. 12 at 7:00 a.m. EDT
Webcast Link: View Source

Event: Life Sciences Investor Forum
Date: Thursday, Sept. 15 at 2 p.m. EDT
Webcast Link: See the Aethlon website for a link to the webcast